Xiaojiang Hao,who obtained Master Degree from Kunming Institute of Botany(KIB),Chinese Academy of Sciences(CAS)in 1985,and Doctor in Pharmacy degree in Pharmacy from Institute for Chemical Research,Kyoto University,in...Xiaojiang Hao,who obtained Master Degree from Kunming Institute of Botany(KIB),Chinese Academy of Sciences(CAS)in 1985,and Doctor in Pharmacy degree in Pharmacy from Institute for Chemical Research,Kyoto University,in 1990,was born in Chongqing in July,1951.In 1991,he returned to KIB,CAS,as an Associate professor and served as the chair of the Department of Phytochemistry.In 1994,he was promoted to a full professor at the current institute.He served as the Deputy Director of KIB and the Director of Open Laboratory of Phytochemistry from 1995 to 1997,and the Director of KIB from 1997 to 2005.Professor Hao has published more than 450 peer-reviewed SCI papers,which have been cited over 6000 times.He has obtained one PCT patent and 23 patents in China.Due to his tremendous efforts,one candidate drug,phenchlobenpyrrone,has entered the Phase II clinical trail for the treatment of Alzheimer’s disease.Moreover,he won the First Prize of Natural Sciences in Yunnan Province for three times,and Ho Leung Ho Lee Fund Science and Technology Innovation Award in 2017.展开更多
文摘Xiaojiang Hao,who obtained Master Degree from Kunming Institute of Botany(KIB),Chinese Academy of Sciences(CAS)in 1985,and Doctor in Pharmacy degree in Pharmacy from Institute for Chemical Research,Kyoto University,in 1990,was born in Chongqing in July,1951.In 1991,he returned to KIB,CAS,as an Associate professor and served as the chair of the Department of Phytochemistry.In 1994,he was promoted to a full professor at the current institute.He served as the Deputy Director of KIB and the Director of Open Laboratory of Phytochemistry from 1995 to 1997,and the Director of KIB from 1997 to 2005.Professor Hao has published more than 450 peer-reviewed SCI papers,which have been cited over 6000 times.He has obtained one PCT patent and 23 patents in China.Due to his tremendous efforts,one candidate drug,phenchlobenpyrrone,has entered the Phase II clinical trail for the treatment of Alzheimer’s disease.Moreover,he won the First Prize of Natural Sciences in Yunnan Province for three times,and Ho Leung Ho Lee Fund Science and Technology Innovation Award in 2017.
